首页> 中文期刊> 《中草药:英文版》 >Shenqi Xingnao Granules ameliorates cognitive impairments and Alzheimer’s disease-like pathologies in APP/PS1 mouse model

Shenqi Xingnao Granules ameliorates cognitive impairments and Alzheimer’s disease-like pathologies in APP/PS1 mouse model

         

摘要

Objective:Alzheimer’s disease(AD)is along with cognitive decline due to amyloid-β(Aβ)plaques,tau hyperphospho rylation,and neuron loss.Shenqi Xingnao Granules(SQXN),a traditional Chinese medicine,significantly ameliorated the cognitive function and daily living abilities of patients with AD.However,till date,no study has investigated the mechanism of action of SQXN on AD.The present study aimed to verify the effects of SQXN treatment on cognitive impairments and AD-like pathologies in APP/PS1 mice.Methods:Four-month-old APP/PS1 transgenic(Tg)mice were randomly divided into a model group and SQXN-treated(3.5,7,14 g/kg per day)groups.Learning-memory abilities were determined by Morris water maze and object recognition test.All mice were sacrificed and the brain samples were collected after 75 d.The soluble Aβcontents were detected by Elisa kit;The levels of expression of NeuN,APP,phosphorylated tau and related protein were measured by Western blotting;The inflammation factors were detected by the proinflammatory panel kit.Results:Four-month-old APP/PS1 mice were administered SQXN by oral gavage for 2.5 months.Using the Morris water maze tests and Novel object recognition,we found that SQXN restored behavioral deficits in the experimental group of Tg mice when compared with the controls.SQXN also inhibited neuronal loss(NeuN marker).SQXN treatment decreased soluble Aβ42 through inhibiting the expression of sAPPβand BACE-1 without regulating full-length amyloid precursor protein(FL APP).Insulin degrading enzyme(IDE),the Aβdegrading enzyme,were increased by SQXN.In addition,SQXN reduced hyperphosphorylated tau protein levels and prevented excessive activation of p-GSK-3βin the brain of APP/PS1 mice.Compared with APP/PS1 transgenic negative mice,IFN-γ,IL-1β,IL-2,IL-4,IL-5,IL-6,IL-12 p70,KC/GRO and TNF-αwere not obviously changed in the brain of 6.5-month-old APP/PS1 transgenic(Tg)mice.However,SQXN could inhibited the expression of IL-2.Conclusion:These results demonstrate that SQXN ameliorates the cognitive impairments in APP/PS1 mice.The possible mechanisms involve its inhibition of neuronal loss,soluble Aβdeposition,tau hyperphosphorylation and inflammation.

著录项

  • 来源
    《中草药:英文版》 |2020年第4期|P.421-429|共9页
  • 作者单位

    Department of Pharmacy Xuanwu Hospital of Capital Medical University Beijing Institute for Brain Disorders Beijing Engineering Research Center for Nerve System Drugs Key Laboratory for Neurodegenerative Diseases of Ministry of Education Beijing 100053 China;

    Department of Pharmacy Xuanwu Hospital of Capital Medical University Beijing Institute for Brain Disorders Beijing Engineering Research Center for Nerve System Drugs Key Laboratory for Neurodegenerative Diseases of Ministry of Education Beijing 100053 China;

    Department of Pharmacy Xuanwu Hospital of Capital Medical University Beijing Institute for Brain Disorders Beijing Engineering Research Center for Nerve System Drugs Key Laboratory for Neurodegenerative Diseases of Ministry of Education Beijing 100053 China;

    Department of Pharmacy Xuanwu Hospital of Capital Medical University Beijing Institute for Brain Disorders Beijing Engineering Research Center for Nerve System Drugs Key Laboratory for Neurodegenerative Diseases of Ministry of Education Beijing 100053 China;

    State Key Laboratory of Cognitive Neuroscience and Learning&IDG/McGovern Institute for Brain Research Beijing Normal University Beijing 100875 ChinaBABRI Centre Beijing Normal University Beijing 100875 China;

    Department of Pharmacy Xuanwu Hospital of Capital Medical University Beijing Institute for Brain Disorders Beijing Engineering Research Center for Nerve System Drugs Key Laboratory for Neurodegenerative Diseases of Ministry of Education Beijing 100053 China;

    Department of Pharmacy Xuanwu Hospital of Capital Medical University Beijing Institute for Brain Disorders Beijing Engineering Research Center for Nerve System Drugs Key Laboratory for Neurodegenerative Diseases of Ministry of Education Beijing 100053 China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 中药实验药理;
  • 关键词

    Aβ; Alzheimer’s disease; APP/PS1; inflammation; neuronal loss; Shenqi Xingnao Granules; tau phosphorylation;

    机译:Aβ;Alzheimer的疾病;APP / PS1;炎症;神经元损失;沉奇Xingnao颗粒;Tau磷酸化;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号